Alzheimer DNA Vaccine and Relativistic Time Dilation

Abstract

In a very recent paper published in November 2017 in the peer-reviewed scientific journal Bio Accent Open Access HIV, I describe a novel procedure designed to improve efficacy of DNA vaccines in areas as diverse as Alzheimer’s disease, HIV infection and cancer [1]. This procedure is based on non-covalent binding of highly charged molecules to DNA; positively charged polyL-lysine is first bound to plasmid DNA. This step is followed by binding of negatively charged chondroitin sulfate to the [polyL-lysine/DNA] complex in a very precise ratio. The third step consists in encasing the resulting [chondroitin sulfate/poly-Llysine/DNA] complexes in a shell of phosphatidylcholine with the formation of a structure similar to liposomes or micelles. This structure reminds the physiological assembly of phospholipids and glycosaminoglycans in human plasma as well as the primeval multi-molecular structures responsible for the origin of life on earth [2]. The implications deriving from the development of this procedure are significant for all those diseases where immunotherapy through DNA vaccination may prove useful. In the field of neurodegenerative diseases, current approaches to immunotherapy of Alzheimer’s disease, although promising, still show a number of limitations and it is anticipated that “More effective and sophisticated vaccines such as DNA vaccine and recombinant viral vaccines will be utilized in future” [3]. The procedure described in Ruggiero [1] may effectively overcome current limitations and increase efficacy of DNA vaccination in Alzheimer’s disease by providing a tool that enhances bioavailability of DNA vaccines and improves immune responses.